Flagship Ventures Fund V, L.P.

Flagship Ventures Fund V, L.P. has an estimated net worth of $252 Million. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., Kaleido Biosciences, Inc., Foghorn Therapeutics Inc., Denali Therapeutics Inc., Rubius Therapeutics, Inc., Codiak BioSciences, Inc., Sigilon Therapeutics, Inc., Evelo Biosciences, Inc., and Omega Therapeutics, Inc..

2020 was Flagship Ventures Fund V, L.P.'s most active year for acquiring shares with 17 total transactions. Flagship Ventures Fund V, L.P.'s most active month to acquire stocks was the month of February. 2023 was Flagship Ventures Fund V, L.P.'s most active year for disposing of shares, totalling 18 transactions. Flagship Ventures Fund V, L.P.'s most active month to dispose stocks was the month of July. 2026 saw Flagship Ventures Fund V, L.P. paying a total of $14,999,766.73 for 4,470,936 shares, this is the most they've acquired in one year. In 2023 Flagship Ventures Fund V, L.P. cashed out on 13,527,995 shares for a total of $17,962,115.86, their largest year based on trade value.